Interventions for Tuberculosis Control and Elimination 2002

1006. Freerksen E, Krüger-Thiemer E, Rosenfeld M. Cycloserin (D-4-Amino-isoxazolidin-3-on).
Antibiotica et Chemotherapia 1959; 6: 303-96.
1007. Shoji JI. Study on orientomycin, identified with D-4-amino-3-isoxazolidone.
Study on actinomyces antibiotics.
9: 164-7.
XXXVII. J Antibiotics Japan Ser A 1965;
1008. Mitui S, Imaizumi S. Study on reduction (eighth report). Identification of orientomycin
and cycloserine (oxamycin, substance PA-94).
Soc Japan Chem Sect 1957; 78: 812-4.
(In Japanese). J Chem
1009. Hidy PH, Hodge EB, Young VV, Harned RL, Brewer GA, Philips WF,
Runge WF, Stavely HE, Pohland A, Boaz H, Sullivan HR. Structure and reactions
of cycloserine. Am Chem Soc 1955; 77: 2345-6.
1010. Benda R, Cans MR, Franchel F, Nataf R. Sur l’emploi d’un nouvel antibiotique
(oxamycine) dans 12 cas de tuberculose pulmonaire.
20: 568-73.
Rev Tuberc 1956;
1011. Kuehl FA, Jr., Wolf FJ, Peck RL, Buhs P, Howe E, Putter I, Hunnewell BD,
Ormond R, Downing G, Lyons JE, Newstead E, Chaiet L, Folkers K. D-4amino-3-isoxazolidone,
a new antibiotic.
1955; 77: 2344-5.
(Correspondence). J Am Chem Soc
1012. Shull GM, Sardinas JL. P-94, an antibiotic identical with D-4-amino-3-isoxazolidinone
(cycloserine, oxamycin). Antibiotics Chemother 1955; 5: 398-9.
1013. Ramaswami S, Musser JM. Molecular genetic basis of antimicrobial agent resistance
in Mycobacterium tuberculosis: 1998 update.
79: 3-29.
Tubercle Lung Dis 1998;
1014. David HL, Goldman DS, Takayama K. Inhibition of the synthesis of wax D
peptidoglycolipid of Mycobacterium tuberculosis by D-cycloserine.
1970; 1: 74-7.
Infect Immun
1015. Iseman MD. Management of multidrug-resistant tuberculosis. Chemotherapy
1999; 45(suppl 2): 3-11.
1016. Walker WC, Murdock JM. Cycloserine in the treatment of pulmonary tuberculosis.
A report on toxicity. Tubercle 1957; 38: 297-302.
1017. Köster E. Klinische Erfahrungen mit Cycloserin bei Lungentuberkulose. Beitr
Klin Tuberk 1957; 117: 317-26.
1018. Vallade L, Hudonenq H, Jude JP. La neuro-toxicité de la cyclosérine. Mise
au point de ses manifestations cliniques et électro-encéphalographiques d’après
30 publications françaises. Presse Méd 1959; 67: 138-40.
1019. Isebarth R, Wiedemann O. D-Cycloserin bei Lungentuberkulose. Bericht über
eine gemeinschaftliche Untersuchung an neun Kliniken.
14: 144-60.
Tuberkulosearzt 1960;
1020. Bucco T, Meligrana G, De Luca V. Neurotoxic effects of cycloserine therapy
in pulmonary tuberculosis of adolescents and young adults.
1970; 71 (Suppl): 259-65.
Scand J Respir Dis
237